[1]Butler D.Translational research:crossing the valley of death[J].Nature, 2008, 453 (7197) :840-842.
|
[2]Geraghty J.Adenomatous polyposis coli and translationalmedicine[J].Lancet, 1996, 348 (9025) :422.
|
[3]Zerhouni E.The NIH Roadmap[J].Science, 2003, 302 (5642) :63-72.
|
[4]Marincola FM.Translational Medicine:A two-way road[J].J Transl Med, 2003, 1 (1) :1-2.
|
[5]Poordad F, McCone J Jr, Bacon BR, et al.Boceprevir foruntreated chronic HCV genotype 1 infection[J].N Engl JMed, 2011, 364 (13) :1195-1206.
|
[6]Jacobson IM, McHutchison JG, Dusheiko G, et al.Telapre-vir for previously untreated chronic hepatitis C virus infection[J].N Engl J Med, 2011, 364 (25) :2405-2416.
|
[7]Zeuzem S, Andreone P, Pol S, et al.Telaprevir for retreat-ment of HCV infection[J].N Engl J Med, 2011, 364 (25) :2417-2428.
|
[8]Hsu CS, Kao JH.Boceprevir for chronic HCV genotype1in-fection[J].N Engl J Med, 2011, 365 (2) :176-177.
|
[9]Ge D, Fellay J, Thompson AJ, et al.Genetic variation inIL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.
|
[10]Rauch A, Kutalik Z, Descombes P, et al.Genetic variation inIL28B is associated with chronic hepatitis C and treatmentfailure:a genome-wide association study[J].Gastroenter-ology, 2010, 138 (4) :1338-1345.
|
[11]Suppiah V, Moldovan M, Ahlenstiel G, et al.IL28B is asso-ciated with response to chronic hepatitis C interferon-alphaand ribavirin therapy[J].Nat Genet, 2009, 41 (10) :1100-1104.
|
[12]Tanaka Y, Nishida N, Sugiyama M, et al.Genome-wideassociation of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C[J].NatGenet, 2009, 41 (10) :1105-1109.
|
[13]Thomas DL, Thio CL, Martin MP, et al.Genetic variation inIL28B and spontaneous clearance of hepatitis C virus[J].Nature, 2009, 461:798-801.
|
[14]Evans TW.Best research for best health:a new nationalhealth research strategy[J].Clin Med, 2006, 6 (5) :435-437.
|
[15]钟世镇.对转化医学与人才培养的感受[J].中华关节外科杂志.电子版, 2011, 5 (2) :208-210.
|